Effects of non-ionic surfactants on cytochrome P450-mediated metabolism in vitro

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 78, Issue 1, 2011, Pages 166-172

  Christiansen, Anne ^a,b   Backensfeld, Thomas ^a   Denner, Karsten ^c   Weitschies, Werner ^b  

^a BAYER PHARMA AG   (Germany)

^b UNIVERSITY OF GREIFSWALD   (Germany)

^c Department of Drug Metabolism and Pharmacokinetics ^*  (Germany)

Author keywords

Bioavailability; Cytochrome P450; Excipients; Inhibition effect; Intestinal metabolism; Non ionic surfactants

Indexed keywords

CREMOPHOR; CYTOCHROME P450 2C9; CYTOCHROME P450 3A4; DEXTRO ALPHA TOCOPHERYL POLYETHYLENE GLYCOL SUCCINATE; DICLOFENAC; NONIONIC SURFACTANT; POLYSORBATE 80; SUCROSE LAURATE; TESTOSTERONE; UNCLASSIFIED DRUG;

ARTICLE; CONCENTRATION RESPONSE; CRITICAL MICELLE CONCENTRATION; DRUG EFFECT; DRUG METABOLISM; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; INHIBITORY CONCENTRATION 50; MASS SPECTROMETRY; MICELLES; SURFACE-ACTIVE AGENTS;

EID: 79953161388     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejpb.2010.12.033     Document Type: Article

References (41)

1. G. Cornaire, J. Woodley, P. Hermann, A. Cloarec, C. Arellano, and G. Houin Impact of excipients on the absorption of P-glycoprotein substrates in vitro and in vivo Int. J. Pharm. 278 1 2004 119 131 (Pubitemid 38670443)
2. J.D.R. Schulze, E.E. Peters, A.W. Vickers, J.S. Staton, M.D. Coffin, G.E. Parsons, and A.W. Basit Excipient effects on gastrointestinal transit and drug absorption in beagle dogs Int. J. Pharm. 300 1-2 2005 67 75 (Pubitemid 41112168)
3. U. Hanke, K. May, V. Rozehnal, S. Nagel, W. Siegmund, W. Weitschies, Commonly used nonionic surfactants interact differently with the human efflux transporters ABCB1 (p-glycoprotein) and ABCC2 (MRP2), Eur. J. Pharm. Biopharm. (2010) Epub ahead of print.
4. X. Ren, X. Mao, L. Si, L. Cao, H. Xiong, J. Qiu, A.D. Schimmer, and G. Li Pharmaceutical excipients inhibit cytochrome P450 activity in cell free systems and after systemic administration Eur. J. Pharm. Biopharm. 70 1 2008 279 288
5. R.J. Mountfield, S. Senepin, M. Schleimer, I. Walter, and B. Bittner Potential inhibitory effects of formulation ingredients on intestinal cytochrome P450 Int. J. Pharm. 211 1-2 2000 89 92 (Pubitemid 32008387)
6. S.-H. Zhou, C.C. Xue, X.-Q. Yu, C. Li, and G. Wang Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring Ther. Drug Monit. 29 6 2007 687 710 (Pubitemid 350190847)
7. D.Y. Gomez, V.J. Wacher, S.J. Tomlanovich, M.F. Hebert, and L.Z. Benet The effects of ketoconazole on the intestinal metabolism and bioavailability of cyclosporine Clin. Pharmacol. Ther. 58 1995 15 19
8. J.T. Backman, K.T. Kivistö, K.T. Olkkola, and P.J. Neuvonen The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin Eur. J. Clin. Pharmacol. 54 1 1998 53 58 (Pubitemid 28189400)
9. F.P. Guengerich CYTOCHROME P-450 3A4: regulation and role in drug metabolism Annu. Rev. Pharmacol. Toxicol. 39 1 1999 1 17 (Pubitemid 29222549)
10. M.F. Paine, H.L. Hart, S.S. Ludington, R.L. Haining, A.E. Rettie, and D.C. Zeldin The human intestinal cytochrome P450 "PIE" Drug Metab. Dispos. 34 5 2006 880 886
11. O.M. John, and J.B. Donald Cytochrome P4502C9: an enzyme of major importance in human drug metabolism Br. J. Clin. Pharmacol. 45 6 1998 525 538
12. K.K. Wolf, M.F. Paine, and P.B. Watkins Metabolic barrier of the gastrointestinal tract Compr. Toxicol. 10 2010 53 75
13. A.E. van Herwaarden, R.A.B. van Waterschoot, and A.H. Schinkel How important is intestinal cytochrome P450 3A metabolism? Trends Pharmacol. Sci. 30 5 2009 223 227
14. R. Strickley Solubilizing excipients in oral and injectable formulations Pharm. Res. 21 2 2004 201 230 (Pubitemid 38221966)
15. C.A. Lipinski Drug-like properties and the causes of poor solubility and poor permeability J. Pharmacol. Toxicol. Methods 44 1 2000 235 249 (Pubitemid 32239479)
16. H. Lennernäs, and B. Abrahamsson The use of biopharmaceutic classification of drugs in drug discovery and development: current status and future extension J. Pharm. Pharmacol. 57 2005 273 285 (Pubitemid 40326200)
17. C.J.H. Porter, N.L. Trevaskis, and W.N. Charman Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs Nat. Rev. Drug. Discov. 6 2007 231 248 (Pubitemid 46344627)
18. N.R. Gursoy, and S. Benita Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs Biomed. Pharmacother. 58 3 2004 173 182 (Pubitemid 38479922)
19. C.W. Pouton Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system Eur. J. Pharm. Sci. 29 3-4 2006 278 287 (Pubitemid 44740131)
20. K.S. Lown, M. Ghosh, and P.B. Watkins Sequences of intestinal and hepatic cytochrome P450 3A4 cDNAs are identical Drug Metab. Dispos. 26 2 1998 185 187 (Pubitemid 28104088)
21. M.M. Nerurkar, N.F. Ho, P.S. Burton, T.J. Vidmar, and R.T. Borchardt Mechanistic roles of neutral surfactants on concurrent polarized and passive membrane transport of a model peptide in Caco-2 cells J. Pharm. Sci. 86 7 1997 813 821 (Pubitemid 27297493)
22. A.P. Villalobos, S.R. Gunturi, and G.A. Heavner Interaction of polysorbate 80 with erythropoiet: a case study in protein surfactant interactions Pharm. Res. 22 7 2005 1186 1194 (Pubitemid 41127077)
23. L.S.C. Wan, and P.F.S. Lee CMC of polysorbates J. Pharm. Sci. 63 1 1974 136 137
24. J.F. Cuiné, C.L. McEvoy, W.N. Charman, C.W. Pouton, G.A. Edwards, H. Benameur, and C.J.H. Porter Evaluation of the impact of surfactant digestion on the bioavailability of danazol after oral administration of lipidic self-emulsifying formulations to dogs J. Pharm. Sci. 97 2 2008 995 1012 (Pubitemid 351293898)
25. A. Christiansen, T. Backensfeld, and W. Weitschies Effects of non-ionic surfactants on in vitro triglyceride digestion and their susceptibility to digestion by pancreatic enzymes Eur. J. Pharm. Sci. 41 2 2010 376 382
26. A. Christiansen, T. Backensfeld, S. Kühn, W. Weitschies, Investigating the stability of the nonionic surfactants tocopheryl polyethylene glycol succinate and sucrose laurate by HPLC-MS, DAD and CAD, J. Pharm. Sci. doi:10.1002/jps.22408. Epub ahead of print.
27. J.C. Price Polyethylene glycol A.H. Kibbe, Handbook of Pharmaceutical Excipients 2000 American Pharmaceutical Association/The Pharmaceutical Press Washington, DC/London, United Kingdom 392 398
28. B.M. Johnson, W.N. Charman, and C.J.H. Porter An in vitro examination of the impact of polyethylene glycol 400, pluronic P85, and vitamin E d-a-Tocopheryl polyethylene glycol 1000 succinate on P-glycoprotein efflux and enterocyte-based metabolism in excised rat intestine AAPS PharmSci. 4 40 2002 1 13
29. D.R. Mudra, and R.T. Borchardt Absorption barriers in the rat intestinal mucosa. 3: effects of polyethoxylated solubilizing agents on drug permeation and metabolism J. Pharm. Sci. 99 2 2010 1016 1027
30. H.T. Yao, Y.W. Chang, S.J. Lan, C.T. Chen, J.T.A. Hsu, and T.K. Yeh The inhibitory effect of polyunsaturated fatty acids on human CYP enzymes Life Sci. 79 26 2006 2432 2440 (Pubitemid 44781104)
31. S. Zhu, R. Huang, M. Hong, Y. Jiang, Z. Hu, C. Liu, and Y. Pei Effects of polyoxyethylene (40) stearate on the activity of P-glycoprotein and cytochrome P450 Eur. J. Pharm. Sci. 37 5 2009 573 580
32. A. Anton, S. Barlow, D. Boskou, L. Castle, R. Crebelli, W. Dekant, K.-H. Engel, S. Forsythe, W. Grunow, M. Heinonen, J.C. Laarsen, C. Leclercq, W. Mennes, M.-R. Milana, I. Pratt, I. Rietjens, K. Svensson, P. Tobback, and F. Toldrá Opinion of the scientific panel on foods additives, flavourings, processing aids and materials in contact with food on sucrose esters of fatty acids, E 473 and sucroglycerides, E 474 based on a request from the commission related to sucrose esters of fatty acids (E 473) EFSA J. 106 2004 1 24
33. M.G. Traber, C.A. Thellman, M.J. Rindler, and H.J. Kayden Uptake of intact TPGS (d - tocopheryl polyethylene glycol 1000 succinate) a water-miscible form of vitamin E by human cells in vitro Am. J. Clin. Nutr. 48 3 1988 605 611
34. B.M. Folmer, D. Barron, E. Hughes, L. Miguet, B. Sanchez, O. Heudi, M. Rouvet, L. Sagalowicz, P. Callier, M. Michel, and G. Williamson Monocomponent hexa- and dodecaethylene glycol succinyl-tocopherol esters: self-assembly structures, cellular uptake and sensitivity to enzyme hydrolysis Biochem. Pharmacol. 78 12 2009 1464 1474
35. R.C. Bravo Gonzáles, J. Huwyler, F. Boess, I. Walter, and B. Bittner In vitro investigation on the impact of the surface-active excipients Cremophor EL, Tween 80 and Solutol HS 15 on the metabolism of midazolam Biopharm. Drug Dispos. 25 1 2004 37 49 (Pubitemid 38159262)
36. B.D. Rege, J.P.Y. Kao, and J.E. Polli Effects of nonionic surfactants on membrane transporters in Caco-2 cell monolayers Eur. J. Pharm. Sci. 16 4-5 2002 237 246
37. D.H. Erin Effects of poly(ethylene glycol) on efflux transporter activity in Caco-2 cell monolayers J. Pharm. Sci. 91 9 2002 1980 1990
38. E.D. Hugger, B.L. Novak, P.S. Burton, K.L. Audus, and R.T. Borchardt A comparison of commonly used polyethoxylated pharmaceutical excipients on their ability to inhibit P-glycoprotein activity in vitro J. Pharm. Sci. 91 9 2002 1991 2002 (Pubitemid 36254935)
39. E.V. Batrakova, S. Li, S.V. Vinogradov, V.Y. Alakhov, D.W. Miller, and A.V. Kabanov Mechanism of pluronic effect on P-glycoprotein efflux system in blood-brain barrier: contributions of energy depletion and membrane fluidization J. Pharmacol. Exp. Ther. 299 2 2001 483 493 (Pubitemid 32979659)
40. K.T. Kivistö, M. Niemi, and M.F. Fromm Functional interaction of intestinal CYP3A4 and P-glycoprotein Fundam. Clin. Pharmacol. 18 6 2004 621 626 (Pubitemid 39564261)
41. V. Oldfield, and G.L. Plosker Lopinavir/Ritonavir: a review of its use in the management of HIV infection Drugs 66 9 2006 1275 1299 (Pubitemid 44055872)